Immunome, Inc.
IMNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $4,015 | $2,926 | $2,738 |
| % Growth | -100% | 37.2% | 6.9% | – |
| Cost of Goods Sold | $49,193 | $720 | $0 | $0 |
| Gross Profit | -$49,193 | $3,295 | $2,926 | $2,738 |
| % Margin | – | 82.1% | 100% | 100% |
| R&D Expenses | $49,193 | $40,451 | $36,872 | $47,890 |
| G&A Expenses | $10,945 | $10,042 | $10,690 | $10,446 |
| SG&A Expenses | $10,945 | $10,042 | $10,690 | $10,446 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$49,193 | -$720 | $0 | $27,372 |
| Operating Expenses | $10,945 | $49,773 | $47,562 | $85,708 |
| Operating Income | -$60,138 | -$46,478 | -$44,636 | -$82,970 |
| % Margin | – | -1,157.6% | -1,525.5% | -3,030.3% |
| Other Income/Exp. Net | $2,681 | $3,081 | $2,996 | $2,721 |
| Pre-Tax Income | -$57,457 | -$43,397 | -$41,640 | -$80,249 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$57,457 | -$43,397 | -$41,640 | -$80,249 |
| % Margin | – | -1,080.9% | -1,423.1% | -2,930.9% |
| EPS | -0.65 | -0.5 | -0.52 | -1.28 |
| % Growth | -30% | 3.8% | 59.4% | – |
| EPS Diluted | -0.65 | -0.5 | -0.52 | -1.28 |
| Weighted Avg Shares Out | 87,958 | 87,011 | 79,410 | 62,704 |
| Weighted Avg Shares Out Dil | 87,958 | 87,011 | 79,410 | 62,704 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,681 | $3,081 | $2,996 | $2,721 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $589 | $720 | $726 | $595 |
| EBITDA | -$56,868 | -$45,758 | -$43,910 | -$55,003 |
| % Margin | – | -1,139.7% | -1,500.7% | -2,008.9% |